Tami L Mark1, Jesse M Hinde2, Gary A Zarkin3, William Parish4, Marianne Kluckman5. 1. RTI International, United States of America. Electronic address: tmark@rti.org. 2. RTI International, United States of America. Electronic address: jhinde@rti.org. 3. RTI International, United States of America. Electronic address: gaz@rti.org. 4. RTI International, United States of America. Electronic address: wparish@rti.org. 5. RTI International, United States of America.
Abstract
BACKGROUND: Although treatment of opioid use disorders (OUD) with medications is expanding, the extent to which practitioners are prescribing medications following best practices has received little attention. OBJECTIVE: The aim of this study was to determine the extent to which privately insured patients being treated for OUD with buprenorphine were treated in a manner consistent with practice guidelines. DESIGN: Longitudinal analyses of a large commercial claims dataset from 2012 to 2016. PARTICIPANTS: We analyzed data for 38,517 patients with an OUD diagnosis continuously enrolled for 3 months prior to and 6 months after an initial buprenorphine or buprenorphine-naloxone prescription fill. MAIN MEASURES: We evaluated whether practitioners tested patients for hepatitis B, hepatitis C, HIV, and liver function; how often they received urine drug screens; the frequency of outpatient visits; and the extent to which they filled prescriptions for buprenorphine for at least 6 months. KEY RESULTS: Practitioners tested approximately 4.7% of patients for hepatitis B, 6.5% for hepatitis C, and 29.3% for HIV; they tested 8.0% for liver functioning; and gave 33.3% urine drug tests. Approximately 76% of patients had at least one outpatient visit for their OUD. Among those with at least one visit, the mean number of visits was 7.38. After the initial prescription, 47.5% stayed on buprenorphine for at least 6 months. CONCLUSIONS: A large portion of privately insured patients receiving buprenorphine for OUD did not receive care consistent with guidelines.
BACKGROUND: Although treatment of opioid use disorders (OUD) with medications is expanding, the extent to which practitioners are prescribing medications following best practices has received little attention. OBJECTIVE: The aim of this study was to determine the extent to which privately insured patients being treated for OUD with buprenorphine were treated in a manner consistent with practice guidelines. DESIGN: Longitudinal analyses of a large commercial claims dataset from 2012 to 2016. PARTICIPANTS: We analyzed data for 38,517 patients with an OUD diagnosis continuously enrolled for 3 months prior to and 6 months after an initial buprenorphine or buprenorphine-naloxone prescription fill. MAIN MEASURES: We evaluated whether practitioners tested patients for hepatitis B, hepatitis C, HIV, and liver function; how often they received urine drug screens; the frequency of outpatient visits; and the extent to which they filled prescriptions for buprenorphine for at least 6 months. KEY RESULTS: Practitioners tested approximately 4.7% of patients for hepatitis B, 6.5% for hepatitis C, and 29.3% for HIV; they tested 8.0% for liver functioning; and gave 33.3% urine drug tests. Approximately 76% of patients had at least one outpatient visit for their OUD. Among those with at least one visit, the mean number of visits was 7.38. After the initial prescription, 47.5% stayed on buprenorphine for at least 6 months. CONCLUSIONS: A large portion of privately insured patients receiving buprenorphine for OUD did not receive care consistent with guidelines.
Authors: Alene Kennedy-Hendricks; Cameron J Schilling; Alisa B Busch; Elizabeth A Stuart; Haiden A Huskamp; Mark K Meiselbach; Colleen L Barry; Matthew D Eisenberg Journal: J Gen Intern Med Date: 2021-08-17 Impact factor: 5.128
Authors: Jason B Gibbons; Jeffrey S McCullough; Kara Zivin; Zach Y Brown; Edward C Norton Journal: JAMA Psychiatry Date: 2022-10-05 Impact factor: 25.911